CervoMed Inc. announced on June 10, 2025, a key senior leadership hire to bolster its Chemistry, Manufacturing, and Controls (CMC) division. Dr. Marco Verwijs, PhD, joined the company in June 2025 as Executive Vice President, Technical Operations.
This strategic appointment is intended to oversee and strengthen the company’s manufacturing capabilities, preparing for scaled-up neflamapimod production. Effective CMC leadership is crucial for ensuring drug quality and supply as a product advances through clinical stages to potential commercialization.
The company remains on track to initiate a Phase 3 trial of neflamapimod in Dementia with Lewy Bodies (DLB) in mid-2026, following planned meetings with regulatory authorities. Dr. Verwijs's role is vital in supporting this progression.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.